The groundbreaking research result of Pharmacoidea Kft., based in Szeged – a new diagnostic procedure for the early detection of Alzheimer’s disease from blood – has been shortlisted at the Reuters Events Pharma Awards in the category “Most Valuable Scientific Breakthrough/Discovery”. Pharmacoidea’s outstanding research has been supported in several projects by the National Research, Development and Innovation Fund and continues to receive support.

Reuters Events, a professional platform linked to the globally renowned Reuters media group, recognises the most significant innovations in the pharmaceutical and biotechnology industries each year. Being shortlisted means that Pharmacoidea’s development is considered by the international jury to be among the most promising and impactful scientific discoveries.

“This nomination is a great recognition not only for us but also for Hungarian research and development, as it provides an opportunity for domestic innovation to gain attention at the leading international forum of the pharmaceutical industry” – said Dr Tamás Letoha, Managing Director of Pharmacoidea.

The awards will be presented at the Reuters Events international conference, attended by the world’s leading pharmaceutical companies and researchers